Quadrant Capital Group LLC Trims Stock Position in GSK plc (NYSE:GSK)

Quadrant Capital Group LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,886 shares of the pharmaceutical company’s stock after selling 370 shares during the period. Quadrant Capital Group LLC’s holdings in GSK were worth $537,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Primecap Management Co. CA increased its position in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after buying an additional 10,407,905 shares in the last quarter. Fisher Asset Management LLC increased its position in GSK by 1.4% during the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after purchasing an additional 259,867 shares in the last quarter. Mondrian Investment Partners LTD increased its position in GSK by 17.6% during the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after purchasing an additional 874,004 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC raised its stake in GSK by 12.0% in the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 4,153,616 shares of the pharmaceutical company’s stock valued at $140,475,000 after purchasing an additional 446,568 shares during the last quarter. Finally, Equity Investment Corp boosted its stake in shares of GSK by 13.3% during the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after purchasing an additional 466,327 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

NYSE:GSK opened at $34.85 on Tuesday. The company has a market cap of $72.12 billion, a P/E ratio of 21.92, a P/E/G ratio of 1.12 and a beta of 0.56. The firm’s 50 day moving average is $37.62 and its two-hundred day moving average is $36.46. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.51%. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is currently 98.74%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.